MedTrace Logo

Advanced Melanoma in Russian Experience

NCT03663647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 382

Last updated 2021-09-29

No results posted yet for this study

Summary

Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation

Conditions

  • Cutaneous Melanoma, Stage IV
  • BRAF V600 Mutation

Sponsors & Collaborators

  • Crocus Medical B.V.

    collaborator UNKNOWN

  • MelanomaPRO, Russia

    lead OTHER

Principal Investigators

  • Kristina Orlova, MD, PhD · Association Professional Melanoma Society (MELANOMA.PRO)

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2019-04-27
Completion
2019-04-27

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03663647 on ClinicalTrials.gov